Developing three-dimensional antisense oligonucleotide drugs against COVID-19
开发针对COVID-19的三维反义寡核苷酸药物
基本信息
- 批准号:10280762
- 负责人:
- 金额:$ 42.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-19 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoV3-DimensionalAcademiaAddressAffectAffinityAlgorithmsAnimal ModelAntisense OligonucleotidesAntiviral AgentsBase PairingBindingBiochemicalBiological Response Modifier TherapyCOVID-19COVID-19 pandemicCOVID-19 treatmentCellsCessation of lifeChemicalsClinical TrialsCommunicable DiseasesComplexCytomegalovirusDataDevelopmentDiseaseElementsEmergency SituationEmerging Communicable DiseasesFeedbackFormulationFoundationsFree EnergyGenetic TranscriptionGenomeGoalsHumanHydrogen BondingIndustryLeadLifeLiteratureMethodsModificationMolecular BiologyMonitorMusMutationNoseNucleic AcidsOligonucleotidesPathogenicityPatternPharmaceutical PreparationsPhylogenetic AnalysisPreventionProductionProgram DevelopmentPropertyProteinsRNARNA VirusesReportingResearchSARS-CoV-2 inhibitorShapesSiteSpecificityStructureSymptomsTechnologyTestingTherapeutic EffectUnited States Food and Drug AdministrationVaccinesVertebral columnViralVirusVirus DiseasesVirus Replicationbasedesigndrug candidatedrug developmentdrug resistant virusfightinghealth care availabilityhigh riskimprovedin vivoinnovationinnovative technologiesintravenous injectionlead optimizationmouse modelnovel drug classnovel therapeuticspandemic diseasepreventremdesivirsynthetic nucleic acidthree dimensional structureviral RNA
项目摘要
Project Summary (Abstract)
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
The culprit of coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome-related
coronavirus-2 (SARS-CoV-2), has a very large RNA genome that encodes the proteins and RNA elements
required for all aspects of viral infection and replication. This property makes the virus vulnerable to a new class
of drugs called antisense oligonucleotide (ASO). ASOs are single-stranded synthetic nucleic acids that achieve
therapeutic effects by binding to viral or other target RNAs via Watson-Crick base pairing, the very interaction
that defines molecular biology and the foundation of life. The first ASO drug approved by the U.S. Food and Drug
Administration is an antiviral against cytomegalovirus. A major challenge of developing ASO antiviral drugs is
the strong tendency of RNA to fold into structures that interfere with ASO hybridization. Current ASO design
methods do not adequately address this problem.
We have developed a structure-based ASO design technology platform that takes advantage of three-
dimensional structures of target RNAs. Our “3D-ASOs” recognize not only the sequences but also the shapes of
SARS-CoV-2 RNAs. Compared to conventional designs, 3D-ASOs contact viral RNAs more extensively and
therefore can achieve greater affinity and specificity. Our technology platform includes four design templates and
a 3D-ASO drug development workflow that employs an innovative RNA structure determination method. In a
preliminary study, we designed and tested several 3D-ASOs against SARS-CoV-2 viral RNA and identified two
lead sequences that strongly inhibit viral replication in cultured human cells to a much greater extent than
previously reported sequences. In the proposed research, we will optimize the lead 3D-ASOs by altering their
backbone modifications and bases for tighter binding and better fit to the viral RNAs and for stronger inhibition
to their functions. We will also cast our net wide by designing and testing additional anti-SARS-CoV-2 3D-ASOs.
Finally, the most potent 3D-ASOs will be tested in an animal model. If successful, the project will provide ASO
drug candidates for clinical trials. These drugs may be given as nasal sprays or via intravenous injection, as
treatments or for prevention. The structure-based design technology we will refine is generally applicable to ASO
drug development. Therefore, this research has the potential to turn tide on the battlefield against COVID-19 and
in our fight with many other diseases.
项目摘要(摘要)
开发抗COVID-19的三维反义寡核苷酸药物
2019冠状病毒病(COVID-19)大流行的罪魁祸首,严重急性呼吸综合征相关
冠状病毒2型(SARS-CoV-2)具有非常大的RNA基因组,其编码蛋白质和RNA元件
病毒感染和复制的各个方面都需要。这种特性使病毒容易受到一个新类的攻击
反义寡核苷酸(阿索)。ASO是单链合成核酸,
通过沃森-克里克碱基配对与病毒或其他靶RNA结合,
定义了分子生物学和生命的基础。美国食品和药物管理局批准的第一个阿索药物
给药是一种抗巨细胞病毒的抗病毒药物。开发阿索抗病毒药物的主要挑战是
RNA折叠成干扰阿索杂交的结构的强烈趋势。当前阿索设计
这些方法不能充分解决这个问题。
我们开发了一个基于结构的阿索设计技术平台,该平台利用了三个方面的优势-
靶RNA的维度结构。我们的“3D-ASO”不仅可以识别序列,还可以识别
SARS-CoV-2 RNA。与常规设计相比,3D-ASO更广泛地接触病毒RNA,
因此可以获得更大的亲和力和特异性。我们的技术平台包括四个设计模板,
3D-ASO药物开发工作流程,采用创新的RNA结构测定方法。中
初步研究,我们设计并测试了几种针对SARS-CoV-2病毒RNA的3D-ASO,并鉴定了两种
在培养的人细胞中强烈抑制病毒复制的前导序列比
先前报道的序列。在拟议的研究中,我们将通过改变其
骨架修饰和碱基,用于更紧密的结合,更好地适合病毒RNA,并具有更强的抑制作用
他们的职能。我们亦会广撒网,设计及测试更多抗SARS-CoV-2的3D-ASO。
最后,最有效的3D-ASO将在动物模型中进行测试。如果成功,该项目将提供阿索
用于临床试验的候选药物。这些药物可以作为鼻喷雾剂或通过静脉注射给药,
治疗或预防。我们将细化的基于结构的设计技术普遍适用于阿索
药物开发因此,这项研究有可能在对抗COVID-19的战场上扭转局势,
in our fight战斗with many许多other diseases疾病.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Feng Guo其他文献
Feng Guo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Feng Guo', 18)}}的其他基金
An automated portable system for detecting and treating opioid induced respiratory depression
用于检测和治疗阿片类药物引起的呼吸抑制的自动化便携式系统
- 批准号:
10592367 - 财政年份:2022
- 资助金额:
$ 42.66万 - 项目类别:
An automated portable system for detecting and treating opioid induced respiratory depression
用于检测和治疗阿片类药物引起的呼吸抑制的自动化便携式系统
- 批准号:
10478481 - 财政年份:2022
- 资助金额:
$ 42.66万 - 项目类别:
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
开发针对COVID-19的三维反义寡核苷酸药物
- 批准号:
10645137 - 财政年份:2021
- 资助金额:
$ 42.66万 - 项目类别:
Developing three-dimensional antisense oligonucleotide drugs against COVID-19
开发针对COVID-19的三维反义寡核苷酸药物
- 批准号:
10453620 - 财政年份:2021
- 资助金额:
$ 42.66万 - 项目类别:
An acoustofluidic avidity cytometer for massive parallel profiling single autoreactive T cell in autoimmune disease
用于大规模平行分析自身免疫性疾病中单个自身反应性 T 细胞的声流控亲和细胞仪
- 批准号:
10002377 - 财政年份:2020
- 资助金额:
$ 42.66万 - 项目类别:
Acoustic assembly of patient tumor organoids for modeling cancer immunity
用于模拟癌症免疫的患者肿瘤类器官的声学组装
- 批准号:
10187568 - 财政年份:2020
- 资助金额:
$ 42.66万 - 项目类别:
Acoustic assembly of patient tumor organoids for modeling cancer immunity
用于模拟癌症免疫的患者肿瘤类器官的声学组装
- 批准号:
10041819 - 财政年份:2020
- 资助金额:
$ 42.66万 - 项目类别:
STRUCTURE OF THE DIMERIZATION DOMAIN OF DIGEORGE CRITICAL REGION 8
DIGEORGE关键区8的二聚化结构域的结构
- 批准号:
8361692 - 财政年份:2011
- 资助金额:
$ 42.66万 - 项目类别:
Molecular recognition and regulation in microRNA processing by the DGCR8 protein
DGCR8 蛋白对 microRNA 加工的分子识别和调控
- 批准号:
7826938 - 财政年份:2007
- 资助金额:
$ 42.66万 - 项目类别:
Molecular recognition and regulation in microRNA processing by the DGCR8 protein
DGCR8 蛋白对 microRNA 加工的分子识别和调控
- 批准号:
7628447 - 财政年份:2007
- 资助金额:
$ 42.66万 - 项目类别:
相似海外基金
REU Site: Design, Create, and Innovate 3-Dimensional User Interfaces to Improve Human Sensory and Motor Performance in Virtual Environments (HUMANS MOVE)
REU 网站:设计、创建和创新 3 维用户界面,以提高虚拟环境中的人类感官和运动表现 (HUMANS MOVE)
- 批准号:
2349771 - 财政年份:2024
- 资助金额:
$ 42.66万 - 项目类别:
Standard Grant
CAREER: Atomic-level understanding of stability and transition kinetics of 3-dimensional interfaces under irradiation
职业:对辐照下 3 维界面的稳定性和转变动力学的原子水平理解
- 批准号:
2340085 - 财政年份:2024
- 资助金额:
$ 42.66万 - 项目类别:
Continuing Grant
Artificial fabrication of 3-dimensional noncollinear magnetic order and magnetization manipulation by spin torque
三维非共线磁序的人工制造和自旋转矩磁化操纵
- 批准号:
23H00232 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Understanding of 3-dimensional seismic behavior of RC frame high-speed railway/highway viaducts using FE analysis
使用有限元分析了解 RC 框架高速铁路/公路高架桥的 3 维抗震性能
- 批准号:
23H01489 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Modernization of 3-dimensional printing capabilities at the Aquatic Germplasm and Genetic Resource Center
水产种质和遗传资源中心 3 维打印能力的现代化
- 批准号:
10736961 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
The 3-dimensional nest of the honey bee: organization, development, and impact on colony function
蜜蜂的 3 维巢穴:组织、发育及其对蜂群功能的影响
- 批准号:
2216835 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Standard Grant
Research on high-density 3-dimensional polymer optical waveguide device for photonics-electronics convergence
光电子融合高密度三维聚合物光波导器件研究
- 批准号:
23H01882 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Scaff-Net: 3 Dimensional multiphoton polymerisation printed scaffolds for medium throughput recording from stem cell derived human cortical networks.
Scaff-Net:3 维多光子聚合打印支架,用于从干细胞衍生的人类皮质网络进行中等通量记录。
- 批准号:
EP/X018385/1 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Research Grant
3-dimensional prompt gamma imaging for online proton beam dose verification
用于在线质子束剂量验证的 3 维瞬发伽马成像
- 批准号:
10635210 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Equipment: MRI: Track 1 Acquisition of a 3-Dimensional Nanolithography Instrument
设备:MRI:轨道 1 获取 3 维纳米光刻仪器
- 批准号:
2320636 - 财政年份:2023
- 资助金额:
$ 42.66万 - 项目类别:
Standard Grant